Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment

@article{Almeida2007PharmacokineticsOE,
  title={Pharmacokinetics of eslicarbazepine acetate in patients with moderate hepatic impairment},
  author={Lu{\'i}s Pereira de Almeida and Jenni-Mar{\'i} Potgieter and Joana Maia and Maria A Potgieter and Fernando Mota and P. Soares-da-Silva},
  journal={European Journal of Clinical Pharmacology},
  year={2007},
  volume={64},
  pages={267-273}
}
ObjectiveTo evaluate the effect of moderate liver impairment on the pharmacokinetics of eslicarbazepine acetate (BIA 2-093, ESL), a novel voltage-gated sodium channel blocker currently in clinical development.MethodsThe pharmacokinetics of ESL following an administration regimen of 800 mg once-daily for 8 days was characterized in patients with moderate liver impairment (n = 8) and in subjects with normal liver function (n = 8, control group).ResultsEslicarbazepine acetate was rapidly and… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 47 CITATIONS

Pharmacokinetics, Drug Interactions and Exposure-Response Relationship of Eslicarbazepine Acetate in Adult Patients with Partial-Onset Seizures

Amílcar Falcão, Eliane Fuseau, Teresa Nunes, Luis Almeida, Patrício Soares-da-Silva
  • CNS Drugs
  • 2012
VIEW 4 EXCERPTS
CITES METHODS & BACKGROUND

Hepatic UDP-glucuronosyltransferase is responsible for eslicarbazepine glucuronidation.

Ana I. Loureiro, Carlos Fernandes-Lopes, Maria João Bonifácio, Lyndon C. Wright, Patrício Soares-da-Silva
  • Drug metabolism and disposition: the biological fate of chemicals
  • 2011
VIEW 1 EXCERPT
CITES BACKGROUND

Exposure‐safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate

Barry E. Gidal, Mercedes P. Jacobson, +11 authors Soujanya Sunkaraneni
  • Acta neurologica Scandinavica
  • 2018

References

Publications referenced by this paper.
SHOWING 1-8 OF 8 REFERENCES